This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

Thursday, 08 November 2018 20:14

UK’s Breast Cancer Screening Glitch

Written by
Rate this item
(0 votes)

by Ian Ellul - Last May, Health Secretary Jeremy Hunt announced that 450,000 women between the ages of 68 and 71 in the UK failed to receive invitations for a final routine breast cancer screening.

Of note, women in the UK from the age of 50 who are registered with a family doctor are automatically invited for screening with a letter every three years until their 71st birthday. Patients cannot ask for an appointment themselves until that age; after that screening requests can be made every three years.

As a result of the 450,000 failed invitations it has been estimated that up to 270 women succumbed to the disease. This gross mistake spanned over a period of almost ten years, between 2009 and Q1 of 2018. The first question is posed … who is to blame? To put it mildly, a computer algorithm failure, involving the programming of people's ages. The second question arises naturally … how was this glitch revealed? Following an upgrade to the breast screening invitation IT system, which allowed for improved data on the actual ages of the women receiving screening invitations.

Further to this, Sheikh and Sasieni studied data from the screening programme between 2004 and 2017, which included looking at the number of eligible women who were sent invitations each year from the ages of 45 to 70. In a letter to Lancet,1 they claim that over 502,000 women may have actually been affected between 2005 and 2018.

It is indeed bewildering how such a grave error went unnoticed for all these years. Obviously this has opened a pandora’s box of medico-legal issues which I will not delve into. However, one needs to clearly discuss how this and related problems can be prevented from happening again through periodic independent audits; this is of special importance considering our gradual increasing reliance on intelligent analytics within the internet of things [it is estimated that 26 billion things will be connected to the internet by 2020]. At this stage, artificial intelligence coupled with blockchain technology may help.  

In simple terms, blockchain is a digital ledger which organizes data and makes it easily accessible. Artificial intelligence, on the other hand, makes it possible to extract intelligent insights from big data. By converging blockchain and artificial intelligence healthcare providers can confirm the accuracy of a diagnosis in a timely manner. The backbone of this is a permissioned ecosystem of trusted collaborators, with additional controls that protect personally identifiable information, while allowing anonymized sharing of personal health information. In keeping with this, in February of 2018, Skychain Global, a blockchain startup, has successfully conducted a medical diagnostics test in Russia, reviewing the number of errors committed by doctors vs the number of errors generated by AI. The test related to the accuracy of melanoma and breast cancer diagnosis as well as the interpretation of ECG results. Of note is the resulting considerable reduction of false positive and false negative results by doctors, which in real life would certainly translate in a reduction in the financial burden of further diagnostic workup, reduction of patient mortality and morbidity, etc. The challenge may be viewed at Indeed, the accumulation of medical big-data in a single ecosystem of machine learning promises exciting applications in the near future.


As Nicholson Price notes in his piece Black Box Medicine,2 medicine “already does and increasingly will use the combination of large-scale high-quality datasets with sophisticated predictive algorithms to identify and use implicit, complex connections between multiple patient characteristics.” This will allow doctors to increase the precision and accuracy of health care diagnosis and decision-making, thereby reducing medical errors. Obviously, an increased reliance on artificial intelligence and machine learning could complicate potential malpractice cases arising from improper treatment as the result of algorithm errors. However, on the other hand,  diagnosis and decision-making algorithms [incorporating failsafe automation systems] may help reduce the costs associated with defensive medicine.




1. Sheikh S, Sasieni P. When should the errors in the UK's breast screening

programme have been spotted? Lancet 2018; pii: S0140-6736(18)31137-1.


  1. Price N. Black-Box Medicine. Harv. J.L. & Tech 2015;28(2):420-467.

Additional Info

  • TheSynapse Magazines: 2016
Read 826 times

Dr Ian Ellul PhD[Paed.][Melit.] has been the managing editor of The Synapse Journal since 2005. He was also Director of Pharmacy Services at a private hospital group, the government's Clinical Trials Coordinator for trials conducted in Malta, as well as senior regulatory affairs officer.  




Connect with other Medical Professionals on fb in a closed facebook group


We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…